<unk>  modulates αβ T cells<unk>  has been shown in in vitro models to specifically modulate αβ T cells. Incubation of peripheral blood monocytes (PBMC) with<unk>  triggers rapid down modulation of the T cell receptor. Importantly, this occurs without T cell proliferation or cytokine induction. Examination of the ability of<unk>  to modulate T cells in a humanized mouse model not only confirmed these in vitro results but also suggested that the T cell modulating capability of the drug occurred in a non-depletional fashion. αβ T cells antibodies in experimental disease models Targeting αβ T cells with antibodies has been tested in numerous experimental models of disease. The data suggests that in models of multiple sclerosis (Experimental autoimmune encephalomyelitis) and type 1 diabetes (Non-obese diabetic mice,) anti-αβ TCR antibody therapy can ameliorate disease symptoms and progression. The precise mechanism through which this occurs remains to be defined, however, it is likely to involve the induction of operational tolerance.
TOL101
BBV154
DEBRA
XPB
CBV 
ESKAPE
OTL-103
JAMA